57 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
in the Department of Thoracic/Head and Neck Medical Oncology, at the University of Texas M.D. Anderson Cancer Center from 1991 to 2011. He also served as Professor … in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program from 2002 to 2011. In 2020, Dr. Herbst was awarded
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at the University of Texas M.D. Anderson Cancer Center from 1991 to 2011. He also … served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program from 2002 to 2011. In 2020, Dr. Herbst
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
by the Export Administration Regulations, and through additional U.S. Commerce Department rulemakings to impose new export control restrictions on “emerging … executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
of Department; should jury service be required this will be on a paid leave of absence basis.
Should you be called on to perform jury service, you should … a member of the HR department, as early as possible on the first day of absence. You must explain the reason for your absence and give as much
8-K
EX-4.1
IMCR
Immunocore Holdings plc
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
or any department or political subdivision thereof or therein or (2) any jurisdiction from or through which payment is made by the Company (or any … Successor Company) or the Paying Agent or any department or political subdivision thereof or therein (each jurisdiction, department or political
6-K
EX-99.2
p4bo7ox
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
vvpfjp5jhy
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
ybytw8kiyp3y1r7u3q7y
10 May 23
Current report (foreign)
7:27am
6-K/A
EX-99.1
meylh3l
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
dhm5u og0
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
zleg2ofl8d lcxk
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
n8pi8aet uipi0t
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
z3ja11n8wh
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-1.1
ueuxbqem64c99u1r
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
r4eu58cv126s2fchly9
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
y0426dgil1
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
fjmjbv p3r77
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
v4xkvnu2fsw fgcrd06i
20 Jul 22
Securities Purchase Agreement
4:06pm
6-K
EX-99.2
ulz0q0wctmafn wa
20 Jul 22
Securities Purchase Agreement
4:06pm
6-K
EX-99.1
2sotlwlp2oyfuth
11 Jul 22
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
4:05pm